Quanterix launches LucentAD biomarker test for early Alzheimer's disease
juststock
Quanterix (NASDAQ:QTRX) said that it has launched a biomarker blood test called LucentAD to help diagnose patients experiencing symptoms consistent with early Alzheimer's disease, or AD.
The diagnostics company said the test allows healthcare professionals to quickly assess the patient for the likelihood of amyloid pathologies associated with AD. The test will be processed by the company's CLIA labs through its new Lucent Diagnostics portal for healthcare professionals. 
Earlier Thursday, the US Food and Drug Administration granted full approval to Biogen (BIIB) and Esai's (OTCPK:ESALF) (OTCPK:ESAIY) Leqembi, also known as lecanemab, for the treatment of mild-to-moderate AD. 
More on Alzheimer's treatments:

Biogen, Eisai win full FDA approval for Alzheimer's drug Leqembi
BioXcel sheds 58% as data integrity issues cloud Alzheimerâs trial win
Cassava Sciences Alzheimerâs drug simufilam outperforms in small trial
AC Immune gains 14% on FDA fast track tag for Alzheimerâs vaccine
Acumen adds 14% on upcoming data for Alzheimerâs candidate